World's Best Scientists 2026 revealed!
Award Badge
Microbiology
USA
2026

D-Index & Metrics

Microbiology

D-Index
129
Citations
73505
World Ranking
80
National Ranking
40

Medicine

D-Index
130
Citations
74110
World Ranking
2463
National Ranking
1392

Joseph J. Eron publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Joseph J. Eron sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 635 publications — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Joseph J. Eron D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Joseph J. Eron sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 129 D-Index — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Microbiology in United States Leader Award
  • 2025 - Research.com Microbiology in United States Leader Award

Overview

Joseph J. Eron is affiliated with the University of North Carolina at Chapel Hill in the United States. Their research primarily focuses on the field of Medicine, with a particular emphasis on Infectious Diseases, Virology, Emergency Medicine, Epidemiology, and Immunology.

The scientist's work centers mainly on HIV/AIDS research and related interventions. Specific topics within this area include HIV research and treatment, HIV/AIDS drug development and treatment, and HIV-related health complications and treatments. In addition to HIV-focused research, Joseph J. Eron also investigates SARS-CoV-2 and COVID-19, including clinical research studies related to COVID-19 and its impact.

Frequent publication venues for Joseph J. Eron's work include:

  • UNC Libraries
  • The Journal of Infectious Diseases
  • Open Forum Infectious Diseases
  • AIDS
  • Clinical Infectious Diseases

Frequent co-authors collaborating with Joseph J. Eron consist of:

  • Richard D. Moore
  • Sonia Napravnik
  • Mari M. Kitahata
  • Michael S. Saag
  • David A. Wohl

Recent notable publications include:

  • Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women, 2021, New England Journal of Medicine
  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults, 2022, JAMA
  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults, 2020, JAMA
  • A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus, 2021, Science Translational Medicine
  • Molnupiravir, an Oral Antiviral Treatment for COVID-19, 2021, bioRxiv (Cold Spring Harbor Laboratory)

Best Publications

  • Prevention of HIV-1 Infection with Early Antiretroviral Therapy

    Myron S. Cohen;Ying Q. Chen;Marybeth McCauley;Theresa Gamble

  • A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less

    Scott M. Hammer;Kathleen E. Squires;Michael D. Hughes;Michael D. Hughes;Janet M. Grimes

  • Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy

    R M Gulick;J W Mellors;D Havlir;J J Eron

  • Antiretroviral Treatment of Adult HIV Infection: 2012 Recommendations of the International Antiviral Society–USA Panel

    Huldrych F Gunthard;Judith A Aberg;Joseph J Eron;Jennifer Frances Hoy

  • Antiretroviral Therapy for the Prevention of HIV-1 Transmission

    Myron S. Cohen;Ying Q. Chen;Marybeth McCauley;Theresa Gamble

  • Effect of early versus deferred antiretroviral therapy for HIV on survival.

    Mari M. Kitahata;Stephen J. Gange;Alison G. Abraham;Barry Merriman

  • Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy

    N. M. Archin;A. L. Liberty;A. D. Kashuba;S. K. Choudhary

  • Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.

    Jacob P. Lalezari;Keith Henry;Mary O'Hearn;Julio S.G. Montaner

  • Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1

    Myron S Cohen;Irving F Hoffman;Rachel A Royce;Peter Kazembe

  • Brief but efficient: acute HIV infection and the sexual transmission of HIV.

    Christopher D. Pilcher;Hsiao Chuan Tien;Joseph J. Eron;Pietro L. Vernazza

  • Initial B-Cell Responses to Transmitted Human Immunodeficiency Virus Type 1: Virion-Binding Immunoglobulin M (IgM) and IgG Antibodies Followed by Plasma Anti-gp41 Antibodies with Ineffective Control of Initial Viremia

    Georgia D. Tomaras;Nicole L. Yates;Pinghuang Liu;Li Qin

  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society–USA Panel

    Huldrych F. Günthard;Michael S. Saag;Constance A. Benson;Carlos del Rio

  • Antiretroviral Treatment of Adult HIV Infection

    Scott M. Hammer;Joseph J. Eron;Peter Reiss;Robert T. Schooley

  • Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

    Raphael J Landovitz;Deborah Donnell;Meredith E Clement;Brett Hanscom

  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel

    Michael S. Saag;Constance A. Benson;Rajesh T. Gandhi;Jennifer F. Hoy

  • Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic Millimeter

    Joseph J. Eron;Sharon L. Benoit;Joseph Jemsek;Rodger David MacArthur

  • Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial

    Beatriz Grinsztejn;Mina C. Hosseinipour;Heather J. Ribaudo;Susan Swindells

  • Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel.

    Unknown

  • A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus

    Unknown

  • Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

    David A. Margolis;Juan Gonzalez-Garcia;Hans Jürgen Stellbrink;Joseph J. Eron

  • Detection of acute infections during HIV testing in North Carolina.

    Christopher D. Pilcher;Susan A. Fiscus;Trang Q. Nguyen;Evelyn Foust

  • The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial

    Joseph Eron;Patrick Yeni;Joseph Gathe;Vicente Estrada

Frequent Co-Authors

Richard D. Moore
Richard D. Moore Johns Hopkins University
Mari M. Kitahata
Mari M. Kitahata University of Washington
Michael S. Saag
Michael S. Saag University of Alabama at Birmingham
Myron S. Cohen
Myron S. Cohen University of North Carolina at Chapel Hill
Susan A. Fiscus
Susan A. Fiscus University of North Carolina at Chapel Hill
Ronald J. Bosch
Ronald J. Bosch Harvard University
Michael J. Mugavero
Michael J. Mugavero University of Alabama at Birmingham
Stephen R. Cole
Stephen R. Cole University of North Carolina at Chapel Hill
Kenneth H. Mayer
Kenneth H. Mayer Harvard Medical School
William C. Miller
William C. Miller The Ohio State University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Microbiology opens up numerous career opportunities, often enhanced by pursuing related online degrees. For those interested in healthcare, exploring online healthcare programs can provide flexible options for further specialization while balancing work and study.

Public health is a natural extension of microbiology, especially in disease prevention and epidemiology. Accredited online MPH programs are an efficient way to advance your knowledge; some of the easiest to get into are detailed in accredited online mph programs easy to get into.

Another related career path involves working closely with children in healthcare settings. Becoming a certified child life specialist often requires CCLS certification, which is thoroughly explained in this guide on ccls certification.

For individuals with a felony record, continuing education and career growth in microbiology and related fields is still possible. Many universities offer supportive options listed under degrees for felons, allowing you to pursue your academic and professional goals without barriers.

Best Scientists Citing Joseph J. Eron

Trending Scientists

Recently Published Articles